Last updated on April 2019

Extension Study for the Port Delivery System With Ranibizumab (Portal)

Brief description of study

This study will evaluate the long-term safety and tolerability of the Port Delivery System (PDS) with ranibizumab 100 mg/mL with refills administered every 24 weeks (Q24W) for approximately 144 weeks in participants with neovascular age-related macular degeneration (nAMD) who have completed either Phase II Study GX28228 or Phase III Study GR40548.

Clinical Study Identifier: NCT03683251

Contact Investigators or Research Sites near you

Start Over

Retina Center of New Jersey

Bloomfield, NJ United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.